A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients

od Tate, Sonya C., Sykes, Amanda K., Kulanthaivel, Palaniappan, Chan, Edward M., Turner, P. Kellie, Cronier, Damien M.
Izdano u Clin Pharmacokinet (2017)

SUMO Pathway Dependent Recruitment of Cellular Repressors to Herpes Simplex Virus Type 1 Genomes

od Cuchet-Lourenço, Delphine, Boutell, Chris, Lukashchuk, Vera, Grant, Kyle, Sykes, Amanda, Murray, Jill, Orr, Anne, Everett, Roger D.
Izdano 2011

PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication

od Cuchet, Delphine, Sykes, Amanda, Nicolas, Armel, Orr, Anne, Murray, Jill, Sirma, Hüseyin, Heeren, Joerg, Bartelt, Alexander, Everett, Roger D.
Izdano 2011

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics

od Chigutsa, Emmanuel, Kambhampati, Siva Rama Prasad, Karen Sykes, Amanda, Posada, Maria M., van der Walt, Jan‐Stefan, Turner, P. Kellie
Izdano u CPT Pharmacometrics Syst Pharmacol (2020)

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers

od Zhang, Jian, Yang, Nong, Ji, Dongmei, Shen, Weina, Li, Wenhua, Han, Rubing, Wang, Ning, Tao, Haoxun, Chapman, Sonya C., Sykes, Amanda K., Zhang, Wanli, Hu, Xichun
Izdano u Target Oncol (2021)

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

od Simon, George R., Ilaria, Robert L., Sovak, Mika A., Williams, Charles C., Haura, Eric B., Cleverly, Ann L., Sykes, Amanda K., Wagner, Margaret M., de Alwis, Dinesh P., Slapak, Christopher A., Miller, Mary A., Spriggs, David R.
Izdano 2011